← Issue №20/ week of Nov 15, 2026/Motility

Endosomal signalling of protease-activated receptor-2 amplifies histamine-induced pain of irritable bowel syndrome.

From GI Signals issue №20: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Motility prospective cohort · Nov 11, 2026 · Gut · IF 24.6

Endosomal signalling of protease-activated receptor-2 amplifies histamine-induced pain of irritable bowel syndrome.

Basic sciencebasic sciencetranslationalbiomarkerIBS
Clinical takeawayNo clinical action yet: a mechanistic finding in mice and in vitro models.
What it foundPAR2 and H1R coactivation in nociceptors amplifies histamine-induced pain, with PAR2 endosomal signaling sustaining hyperexcitability in IBS-related colonic pain.
ContextThis study elucidates a novel mechanism of IBS pain, focusing on PAR2 and H1R interaction, which challenges the current understanding of transient histamine effects.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Jimenez-Vargas NN … Bunnett NW · Gut · IF 24.6 · PubMed ↗Permalink
← Read the whole of issue №20 Every paper GI Signals surfaces gets a page like this one. All issues